Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study (Q25257445)

1 June 2018

title

Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study (English)

1 reference

1 June 2018

metastatic hepatocellular carcinoma

main subject

chemotherapy

0 references

1 reference

1 reference

1 reference

1 reference

2

Jin Eun Choi

1 reference

1 June 2018

Jae Yong Park

11

Jae Yong Park

1 reference

1 June 2018

Chang Ho Kim

7

Chang Ho Kim

1 reference

1 June 2018

Won Kee Lee

4

Won Kee Lee

1 reference

1 June 2018

Myung Hwa Chae

3

Myung Hwa Chae

1 reference

1 June 2018

Sung Ick Cha

5

Sung Ick Cha

1 reference

1 June 2018

Sin Kam

8

Sin Kam

1 reference

1 June 2018

Tae Hoon Jung

10

Tae Hoon Jung

1 reference

1 June 2018

author name string

Jung Min Park

1

1 reference

1 June 2018

Ji-Woong Son

6

1 reference

1 June 2018

Young Mo Kang

9

1 reference

1 June 2018

language of work or name

English

0 references

publication date

17 March 2006

1 reference

1 June 2018

published in

BMC Cancer

1 reference

1 June 2018

volume

6

1 reference

1 June 2018

issue

1

0 references

page(s)

70

1 reference

1 June 2018

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Systemic therapy for advanced hepatocellular carcinoma: a review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Classification of chronic hepatitis: diagnosis, grading and staging

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Primary hepatocellular cancer--present results and future prospects.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

Optimal two-stage designs for phase II clinical trials

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1352374

DNMT3B polymorphisms and risk of primary lung cancer

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Genetic susceptibility to lung cancer: the role of DNA damage and repair.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Aspirin and lung cancer in women

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Cyclooxygenases: structural, cellular, and molecular biology

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Searching for genetic determinants in the new millennium

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Cancer risk and low-penetrance susceptibility genes in gene-environment interactions

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Expression of cyclooxygenase-2 in human lung carcinoma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Cyclooxygenase in biology and disease

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3'-untranslated region

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Regulation of the immune response by prostaglandins

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals

2 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

Cyclooxygenase-2 gene expression in human breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Characterization of a cyclooxygenase-2-765G-->C promoter polymorphism in human neural cells

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

XPC polymorphisms and lung cancer risk.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

SNPs, haplotypes, and cancer: applications in molecular epidemiology.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Point: myeloperoxidase -463G --> a polymorphism and lung cancer risk.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Prostaglandin E2 increases growth and motility of colorectal carcinoma cells

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Characteristics of lung cancer in Korea, 1997

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1468421

Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas

28 November 2018

1 reference

12 December 2020

The p53 codon 72 polymorphism and lung cancer risk

1 reference

12 December 2020

The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency

1 reference

12 December 2020

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2

1 reference

12 December 2020

p73 G4C14-to-A4T14 polymorphism and risk of lung cancer

1 reference

12 December 2020

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

7 January 2021

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

7 January 2021

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

7 January 2021

Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

7 January 2021

Non-surgical treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-3

7 January 2021

Identifiers

DOI

10.1186/1471-2407-6-3

1 reference

1 June 2018

Dimensions Publication ID

0 references

1 reference

1 June 2018

PubMed publication ID

16542464

1 reference

1 June 2018